📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
151,859
All-time analysed
43,535
Positive
6,743
Negative
92,744
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
Mangalam Drugs Reports Q3 Revenue Decline to ₹58.49 Cr; CFO and CS Resign
Mangalam Drugs and Organics reported a significant decline in consolidated revenue for Q3 FY26, falling to ₹58.49 crore from ₹88.71 crore in the same quarter last year. The company faced an operational loss as total expenses of ₹64.38 crore exceeded its total income for the quarter. Adding to the financial pressure, the company announced the resignations of two Key Managerial Personnel: the Chief Financial Officer (CFO) and the Company Secretary. The 9-month performance also shows a sharp downward trend, with revenue dropping nearly 32% year-on-year.
Key Highlights
Consolidated revenue for Q3 FY26 fell 34% YoY to ₹58.49 crore from ₹88.71 crore.
Total expenses for the quarter stood at ₹64.38 crore, leading to an operational loss before other income and tax.
9-month revenue for FY26 declined to ₹165.38 crore compared to ₹245.19 crore in the previous year period.
CFO Ajay Samant resigned effective January 31, 2026, citing health reasons.
Company Secretary Anuradha Pandey resigned effective March 29, 2026, to pursue other opportunities.
👀 What to Watch
Investors should exercise caution as the company is struggling with both declining top-line performance and the simultaneous exit of key leadership. It is advisable to wait for signs of operational stabilization and the appointment of new management before considering new positions.
Mangalam Drugs Defaults on ₹11.54 Crore Loan Payments to PSU Banks
Mangalam Drugs and Organics Limited has reported a subsequent default on its cash credit facilities with Bank of Baroda and Bank of Maharashtra. As of December 17, 2025, the total overdue amount stands at ₹1,153.76 Lacs. The default has persisted for more than 30 days, triggering mandatory disclosure under SEBI (LODR) Regulations. The company's management has stated that they are making arrangements to settle the overdue amounts as soon as possible.
Key Highlights
Total overdue amount of ₹1,153.76 Lacs across two major public sector banks
Default of ₹707.05 Lacs to Bank of Maharashtra on cash credit account
Default of ₹446.71 Lacs to Bank of Baroda on cash credit account
Default duration has exceeded the 30-day threshold for revolving facilities
Management is currently arranging funds to clear the outstanding dues
👀 What to Watch
Investors should exercise extreme caution as loan defaults indicate severe liquidity stress and potential solvency issues. Monitor for any further credit rating downgrades or legal actions by the lending banks.
Mangalam Drugs Defaults on Rs 11.54 Crore Loan Payments to PSU Banks
Mangalam Drugs and Organics Limited has officially disclosed defaults on its cash credit facilities with Bank of Maharashtra and Bank of Baroda. The total overdue amount is approximately Rs 11.54 crore, which has remained unpaid for over 30 days. Specifically, the company owes Rs 7.07 crore to Bank of Maharashtra and Rs 4.47 crore to Bank of Baroda. Management has indicated that they are currently making arrangements to settle these overdue amounts as soon as possible.
Key Highlights
Total default amount of Rs 11.54 crore reported across two bank accounts.
Rs 707.05 Lacs overdue to Bank of Maharashtra with default starting October 17, 2025.
Rs 446.77 Lacs overdue to Bank of Baroda with default starting October 20, 2025.
Defaults have persisted for more than 30 days, triggering mandatory SEBI disclosure requirements.
The company is currently seeking arrangements to clear the outstanding dues.
👀 What to Watch
Investors should exercise extreme caution as debt defaults are a major red flag indicating severe liquidity stress. Monitor for potential credit rating downgrades and the company's ability to clear these dues in the immediate term.
